Live Breaking News & Updates on Travere therapeutic

Stay informed with the latest breaking news from Travere therapeutic on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Travere therapeutic and stay connected to the pulse of your community

HC Wainwright Increases Travere Therapeutics (NASDAQ:TVTX) Price Target to $19.00

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its price objective increased by HC Wainwright from $17.00 to $19.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 252.50% from the company’s current price. HC […]

Piper-sandler , Ericm-dube , Jacobs-levy-equity-management-inc , Wells-fargo-company , Vanguard-group-inc , Travere-therapeutics-inc , Armistice-capital , Travere-therapeutics , Get-free-report , Travere-therapeutic , Therapeutics-stock-down , Capital-management

Travere Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($1.80) Per Share (NASDAQ:TVTX)

Travere Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($1.80) Per Share (NASDAQ:TVTX)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Christopherr-cline , Piper-sandler , Peter-heerma , Vanguard-group-inc , Nasdaq , Jacobs-levy-equity-management-inc , Armistice-capital , Wells-fargo-company , Travere-therapeutics-inc , Travere-therapeutics , Free-report , Travere-therapeutic

Travere Therapeutics, Inc. (NASDAQ:TVTX) Forecasted to Post FY2028 Earnings of $4.29 Per Share

Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Equities researchers at HC Wainwright cut their FY2028 earnings estimates for Travere Therapeutics in a report issued on Wednesday, April 24th. HC Wainwright analyst E. Arce now forecasts that the company will earn $4.29 per share for the year, down from their previous estimate of $4.66. HC […]

Ericm-dube , Peter-heerma , Piper-sandler , Travere-therapeutics-inc , Wells-fargo-company , Nasdaq , Vanguard-group-inc , Healthcare-of-ontario-pension-plan-trust-fund , Travere-therapeutics , Free-report , Travere-therapeutic , Get-free-report

FY2026 EPS Estimates for Travere Therapeutics, Inc. (NASDAQ:TVTX) Decreased by Analyst

FY2026 EPS Estimates for Travere Therapeutics, Inc. (NASDAQ:TVTX) Decreased by Analyst
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Stifel-nicolaus , Ericm-dube , Peter-heerma , Piper-sandler , Huntington-national-bank , Nisa-investment-advisors , Nasdaq , Travere-therapeutics-company-profile , Us-bancorp , Travere-therapeutics-inc , Wells-fargo-company , Citigroup

CHMP says yes to Tavere's Filspari and to several other meds

CHMP says yes to Tavere's Filspari and to several other meds
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United-states , Japan , Beigene-tizveni , Edmond-chan , Callidita-tarpeyo , Johnson-carvykti , Ioni-qalsody , Astrazeneca-voydeya , Merck-keytruda , Bristol-myers-squibb-reblozyl , Incyte-zynyz , European-union

Assembly Biosciences (NASDAQ:ASMB) & Travere Therapeutics (NASDAQ:TVTX) Critical Comparison

Assembly Biosciences (NASDAQ:ASMB) & Travere Therapeutics (NASDAQ:TVTX) Critical Comparison
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

San-diego , California , United-states , Taiwan , Hong-kong , Republic-of-china , Taiwan-general- , Macau , South-san-francisco , Retrophin-inc , Arbutus-biopharma-corporation

HC Wainwright Equities Analysts Lower Earnings Estimates for Travere Therapeutics, Inc. (NASDAQ:TVTX)

HC Wainwright Equities Analysts Lower Earnings Estimates for Travere Therapeutics, Inc. (NASDAQ:TVTX)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Stifel-nicolaus , Piper-sandler , William-blair , Travere-therapeutics-company-profile , Group-plc , Nasdaq , Travere-therapeutics-inc , Jacobs-levy-equity-management-inc , Vanguard-group-inc , Manufacturers-life-insurance-company , Ameriprise-financial-inc

US FDA approves Sweden-based Calliditas' kidney disease drug

(Reuters) -The U.S. Food and Drug Administration (FDA) granted full approval to Swedish drugmaker Calliditas Therapeutics' drug to treat rare kidney disease IgA Nephropathy (IgAN), the company said on Wednesday. The FDA decision makes the drug, branded as Tarpeyo, the first to be granted a full approval in the United States for IgAN, ahead of Travere Therapeutics' Filspari which won accelerated approval earlier this year. The health regulator in 2021 granted accelerated approval to Tarpeyo for adults with primary IgAN to reduce increased protein levels in the urine, a condition called proteinuria.

Sweden , Bengaluru , Karnataka , India , United-states , Swedish , Sriparna-roy , Shounak-dasgupta , Shinjini-ganguli , Christy-santhosh , Reuters , Drug-administration

US FDA approves Sweden-based Calliditas' kidney disease drug

(Reuters) -The U.S. Food and Drug Administration (FDA) granted full approval to Swedish drugmaker Calliditas Therapeutics' drug to treat rare kidney disease IgA Nephropathy (IgAN), the company said on Wednesday. The FDA decision makes the drug, branded as Tarpeyo, the first to be granted a full approval in the United States for IgAN, ahead of Travere Therapeutics' Filspari which won accelerated approval earlier this year. The health regulator in 2021 granted accelerated approval to Tarpeyo for a

Sweden , United-states , Bengaluru , Karnataka , India , Swedish , Sriparna-roy , Shounak-dasgupta , Christy-santhosh , Shinjini-ganguli , Drug-administration , Reuters

Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance

12.12.2023 - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand’s senior management team provided an overview of the company’s business model and ... Seite 1

Boston , Massachusetts , United-states , New-york , Todd-davis , Verona-pharma , Ligand-pharmaceuticals-incorporated , Ligand-holds-investor , Analyst-day , Provides-update , Portfolio-progress , Recent-transactions